Days after the FDA communicated to Lykos Therapeutics that it would not approve MDMA-assisted therapy for PTSD at this time, the company’s CEO, Amy Emerson, penned a letter to the agency’s Commissioner, Robert Califf. In the letter (PDF), Emerson provides the company’s feedback on the Advisory Committee (AdComm) process generally, as well as Lykos’ own ill-fated meeting (see Analysis…
